Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanxiang Ruzengxiao is a Traditional Chinese Medicine (TCM) formulation developed by Shaanxi Xingbang Pharmaceutical Co., Ltd., primarily indicated for the treatment of breast hyperplasia (hyperplasia of mammary glands). The formulation is typically administered in capsule form and is composed of several herbal ingredients, including *Cyperus rotundus* (Xiangfu), *Curcuma phaeocaulis* (Ezhu), and *Sparganium stoloniferum* (Sanleng). Based on TCM principles, the drug functions to soothe the liver, regulate qi circulation, activate blood flow, and resolve phlegm to soften hard masses. Clinically, it is used to alleviate breast pain and reduce the size of breast nodules or masses associated with qi stagnation and blood stasis. It is approved for marketing in China under the NMPA registration number 国药准字Z20025071.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanxiang Ruzengxiao.